Unusual case of duodenobiliary fistula complicating Crohn's disease successfully treated with Adalimumab

Arab J Gastroenterol. 2016 Dec;17(4):188-190. doi: 10.1016/j.ajg.2016.11.004. Epub 2016 Dec 9.

Abstract

Crohn's disease (CD) is characterized by transmural inflammation of the gastrointestinal tract, which predisposes to the formation of fistula. Duodenal involvement occurs in less than 5% of cases and often leads to clinically relevant strictures. However, fistula formation in the duodenum is exceptional. Herein, we report an unusual case of duodenobiliary fistula due to CD occurring in a 65-year-old patient who was successfully treated by anti-tumor necrosis factor (TNF) agents. This case report highlights the efficacy of anti-TNF alpha agents in the treatment of a bilioenteric fistula because it increases the probability of clinical remission and mucosal healing and therefore reduces the need for surgical treatment which may be associated morbidity.

Keywords: Anti-TNF agents; Crohn’s disease; Duodenobiliary fistula; Duodenum stricture; Transmural inflammation.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / therapeutic use*
  • Aged
  • Anti-Inflammatory Agents / therapeutic use*
  • Bile Duct Diseases / complications*
  • Bile Duct Diseases / drug therapy
  • Biliary Fistula / complications*
  • Biliary Fistula / drug therapy
  • Crohn Disease / complications*
  • Crohn Disease / drug therapy*
  • Duodenal Diseases / complications*
  • Duodenal Diseases / drug therapy
  • Female
  • Humans
  • Intestinal Fistula / complications*
  • Intestinal Fistula / drug therapy

Substances

  • Anti-Inflammatory Agents
  • Adalimumab